265 related articles for article (PubMed ID: 33634371)
1. TIGIT promotes CD8
Liang R; Zhu X; Lan T; Ding D; Zheng Z; Chen T; Huang Y; Liu J; Yang X; Shao J; Wei H; Wei B
Cancer Immunol Immunother; 2021 Oct; 70(10):2781-2793. PubMed ID: 33634371
[TBL] [Abstract][Full Text] [Related]
2. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
3. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
Li S; Ding J; Wang Y; Wang X; Lv L
J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
[TBL] [Abstract][Full Text] [Related]
5. Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma.
Xie X; Feng Y; Fan P; Dong D; Yao X; Peng Y; Wang R
Biomol Biomed; 2023 Jul; 23(4):584-595. PubMed ID: 36913701
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
7. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
8. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
Front Immunol; 2018; 9():2821. PubMed ID: 30555485
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral TIGIT
Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
[TBL] [Abstract][Full Text] [Related]
10. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
11. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
12. TIGIT presents earlier expression dynamic than PD-1 in activated CD8
Hu F; Wang W; Fang C; Bai C
Exp Cell Res; 2020 Nov; 396(1):112260. PubMed ID: 32890458
[TBL] [Abstract][Full Text] [Related]
13. TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism.
Shao Q; Wang L; Yuan M; Jin X; Chen Z; Wu C
Front Immunol; 2021; 12():688961. PubMed ID: 34659197
[TBL] [Abstract][Full Text] [Related]
14. Blocking TIGIT/CD155 signalling reverses CD8
Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
[TBL] [Abstract][Full Text] [Related]
15. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
[TBL] [Abstract][Full Text] [Related]
16. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
17. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
18. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer.
Saleh R; Taha RZ; Toor SM; Sasidharan Nair V; Murshed K; Khawar M; Al-Dhaheri M; Petkar MA; Abu Nada M; Elkord E
Cancer Immunol Immunother; 2020 Oct; 69(10):1989-1999. PubMed ID: 32393998
[TBL] [Abstract][Full Text] [Related]
19. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
20. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
